Salvage Strategies for Management of Testicular Tumors

被引:0
|
作者
Chatterjee S. [1 ]
Rawal S.K. [1 ]
机构
[1] Department of Surgical Oncology and Uro-oncology, Rajeev Gandhi Cancer Institute and Research Centre, Rohini Sector 5, New Delhi
关键词
Cisplatin; Testicular cancer; Testicular tumors;
D O I
10.1007/s13193-016-0614-1
中图分类号
学科分类号
摘要
Testicular germ cell tumors (GCTs) comprise 2% of all human male malignancies and are the most common solid tumors in men between ages 15 and 35 years. Risk of contralateral testicular GCT is between 1 and 5%. Partial orchidectomy (PO) was originally described in 1984 by Richie. The evolving indications include metachronous tumors and tumor in solitary testicles. Also, small non-palpable lesions detected only by ultrasonography (USG) in asymptomatic patients is another indication. Salvagability is only chosen for tumors less than 2 cm in size. The key feature of PO is an inguinal approach with early vascular control using a rubber tourniquet before testicular mobilization into the field to avoid systemic tumor seeding. After, mass excision with a margin mandatory frozen section is done to assess adequacy of resection. Intra-op USG may be beneficial in small non-palpable lesions. Post op tumor markers are assessed and patients are taught self-examination of testis. Recent series shows that PO is safe and gives adequate oncological control. Carcinoma in situ (CIS) in the affected testis at PO or after testicular sparing surgery remains a challenge. At most centers, 20 Gy is recommended when adjuvant local radiation treatment is chosen to treat CIS. But this dose may hamper Androgen production. Radical orchiectomy remains the gold standard and should be discussed as part of informed consent. It is mandatory to highlight the risks of local recurrence and CIS, and treatment (observation, radiation, or completion orchiectomy) as well as the need for androgen supplementation and fertility risks before choosing testicular salvage procedures. © 2016, Indian Association of Surgical Oncology.
引用
收藏
页码:389 / 396
页数:7
相关论文
共 50 条
  • [41] Bilateral testicular tumors - Management and outcome in 21 patients
    Coogan, CL
    Foster, RS
    Simmons, GR
    Tognoni, PG
    Roth, BJ
    Donohue, JP
    CANCER, 1998, 83 (03) : 547 - 552
  • [42] Conservative management of testicular germ-cell tumors
    Tim Oliver
    Nature Clinical Practice Urology, 2007, 4 : 550 - 560
  • [43] CLINICAL MANAGEMENT OF NON-TESTICULAR INTRASCROTAL TUMORS
    BECCIA, DJ
    KRANE, RJ
    OLSSON, CA
    JOURNAL OF UROLOGY, 1976, 116 (04): : 476 - 479
  • [44] Conservative management of testicular germ-cell tumors
    Oliver, Tim
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (10): : 550 - 560
  • [45] Strategies for management of malignant brain tumors
    Zervas, NT
    BRAIN PATHOLOGY, 1997, 7 (04) : 1229 - 1230
  • [46] Management strategies for tumors of the axis vertebra
    Piper, JG
    Menezes, AH
    JOURNAL OF NEUROSURGERY, 1996, 84 (04) : 543 - 551
  • [47] COMPARING RADIATION EXPOSURE OF TESTICULAR CANCER MANAGEMENT STRATEGIES
    Wang, Agnes J.
    Lipkin, Michael E.
    Preminger, Glenn M.
    Neville, Amy M.
    Ferrandino, Michael N.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E236 - E236
  • [48] New Anti-Cancer Strategies in Testicular Germ Cell Tumors
    Chieffi, Paolo
    De Martino, Marco
    Esposito, Francesco
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2019, 14 (01) : 53 - 59
  • [49] COMBINATION SALVAGE CHEMOTHERAPY USING CISPLATIN AND TENIPOSIDE FOR PATIENTS WITH REFRACTORY GERMINAL TESTICULAR-TUMORS
    KOTAKE, T
    MIKI, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (02) : 85 - 88
  • [50] Management of poor-prognosis testicular germ cell tumors
    Khurana, Kiranpreet
    Gilligan, Timothy D.
    Stephenson, Andrew J.
    INDIAN JOURNAL OF UROLOGY, 2010, 26 (01) : 108 - 114